Cytokine-based tumor cell vaccine is equally effective against parental and isogenic multidrug-resistant myeloma cells: The role of cytotoxic T lymphocytes

Blood

Volumn 93, Issue 6, 1999, Pages 1831-1837

  Shtil, Alexander A ^a,b   Turner, Joel G ^a,b   Durfee, John ^a,b   Dalton, William S ^a,b   Yu, Hua ^a,b  

^a H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

^b UNIVERSITY OF SOUTH FLORIDA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CONCANAMYCIN A; DEXAMETHASONE; DOXORUBICIN; FAS LIGAND; GLYCOPROTEIN P; GRANZYME B; MELPHALAN; MITOXANTRONE; PERFORIN; TUMOR CELL VACCINE; VINCRISTINE;

ANIMAL EXPERIMENT; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER THERAPY; CYTOLYSIS; CYTOTOXIC T LYMPHOCYTE; FEMALE; MOUSE; MULTIDRUG RESISTANCE; MULTIPLE MYELOMA; MYELOMA CELL; NEWBORN; NONHUMAN; PRIORITY JOURNAL; TUMOR GROWTH; VACCINATION;

EID: 0033560099     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood.v93.6.1831.406k38_1831_1837     Document Type: Article

References (40)

1. Shustik C, Dalton W, Gros P: P-glycoprotein-mediated multidrug resistance in tumor cells: Biochemistry, clinical relevance and modulation. Mol Aspects Med 16:1, 1995
2. Dalton WS, Grogan TM, Rybski JA, Scheper RJ, Richter L, Kailey J, Broxterman HJ, Pinedo HM, Salmon SE: Immunohistochemical detection and quantitation of P-glycoprotein in multiple drug-resistant human myeloma cells: Association with level of drug resistance and drug accumulation. Blood 73:747, 1989
3. Musto P, Lombardi G, Matera R, Carotenuti M: The expression of the multidrug transporter P-170 glycoprotein in remission phase is associated with early and resistant relapse in multiple myeloma. Haematologica 76:513, 1991
4. Nooter K, Sonneveld P: Clinical relevance of P-glycoprotein expression in haematological malignancies. Leuk Res 18:233, 1994
5. Kwak LW, Young HA, Pennington RW, Weeks SD: Vaccination with syngeneic, lymphoma-derived immunoglobulin idiotype combined with granulocyte-macrophage colony-stimulating factor primes mice for a protective T-cell response. Proc Natl Acad Sci USA 93:10972, 1996
6. Hsu FJ, Benike C, Fagnoni F, Liles TM, Czerwinski D, Taidi B, Engleman EG, Levy R: Vaccination of patients with B-cell lymphoma using autologous antigen-pulsed dendritic cells. Nat Med 2:52, 1996
7. Hsu FJ, Caspar CB, Czerwinski D, Kwak LW, Liles TM, Syrengelas A, Taidi-Laskowski B, Levy R: Tumor-specific idiotype vaccines in the treatment of patients with B-cells lymphoma - Long-term results of a clinical trial. Blood 89:3129, 1997
8. Kwak LW, Campbell MJ, Czerwinski DK, Hart S, Miller RA, Levy R: Induction of immune responses in patients with B-cell lymphoma against the surface-immunoglobulin idiotype expressed by their tumors. N Engl J Med 327:1209, 1992
9. Dranoff G, Jaffee E, Lazenby A, Golumbek P, Levitsky H, Brose K, Jackson V, Hamada H, Pardoll D, Mulligan RC: Vaccination with irradiated tumor cells engineered to secrete murine granulocyte-macrophage colony-stimulating factor stimulates potent, specific, and long-lasting anti-tumor immunity. Proc Natl Acad Sci USA 90:3539, 1993
10. Levitsky HI, Montgomery J, Ahmadzadeh M, Staveley-O'Carroll K, Guarnieri F, Longo DL, Kwak LW: Immunization with granulocyte-macrophage colony-stimulating factor-transduced, but not B7-1-transduced, lymphoma cells primes idiotype-specific T cells and generates potent systemic antitumor immunity. J Immunol 156:3858, 1996
11. Turner JG, Tan J, Crucian BE, Sullivan DM, Ballester OF, Dalton WS, Yang N-S, Burkholder JK, Yu H: Broadened clinical utility of gene gun-mediated, granulocyte-macrophage colony-stimulating factor cDNA-based tumor cell vaccines as demonstrated with a mouse myeloma model. Hum Gene Ther 9:1121, 1998
12. Woods GW, Lund LA, Naik M, Ling V, Ochi A: Resistance of multidrug-resistant lines to natural killer-like cell-mediated cytotoxicity. FASEB J 2:2791, 1988
13. Yanovich S, Hall RE, Weinert C: Resistance to natural killer cell-mediated cytolysis by a pleiotropic drug-resistant human erythroleukemia (K562-R) cell line. Cancer Res 46:4511, 1986
14. Kimmig A, Gekeler V, Neumann M, Frese G, Handgreitinger R, Kardos G, Diddens H, Niethammer D: Susceptibility of multidrug-resistant human leukemia cell lines to human interleukin 2-activated killer cells. Cancer Res 50:6793, 1990
15. Scheper RJ, Dalton WS, Grogan TM, Schlosser A, Bellamy WT, Taylor CW, Scuderi P, Spier C: Altered expression of P-glycoprotein and cellular adhesion molecules on human multi-drug-resistant tumor cells does not affect their susceptibility to NK-and LAK-mediated cytotoxicity. Int J Cancer 48:562, 1991
16. Kwak LW, Taub DD, Duffey PL, Bensinger WI, Bryant EM, Reynolds CW, Longo DL: Transfer of myeloma idiotype-specific immunity from an actively immunized marrow donor. Lancet 345:1010, 1995
17. Osterborg A, Yi Q, Henriksson L, Fagerberg J, Bergenbrant S, Jeddi-Tehrani M, Ruden V, Lefvert AK, Holm G, Mellstedt H: Idiotype immunization combined with granulocyte-macrophage colony-stimulating factor in myeloma patients induced type I, major histocompatibility complex-restricted, CD8- and CD4-specific T-cell responses. Blood 91:2549, 1998
18. Wen YJ, Ling M, Bailey-Wood R, Lim SH: Idiotypic protein-pulsed adherent peripheral blood mononuclear cell-derived dendritic cells prime immune system in multiple myeloma. Clin Cancer Res 4:957, 1998
19. Berke G: The CTL's kiss of death. Cell 81:9, 1995
20. Hahn S, Gehri R, Erb P: Mechanism and biological significance of CD4-mediated cytotoxicity. Immunol Rev 146:57, 1995
21. Shima Y, Nishimoto N, Ogata A, Fujii Y, Yoshizaki K, Kishimoto T: Myeloma cells express Fas antigen/APO-1 (CD95) but only some are sensitive to anti-Fas antibody resulting in apoptosis. Blood 85:757, 1995
22. Landowski TH, Gleason-Gusman MC, Dalton WS: Selection for drug resistance results in resistance to Fas-mediated apoptosis. Blood 89:1854, 1997
23. Smyth MJ, Krasovskis E, Sutton VR, Johnstone RW: The drug efflux protein, P-glycoprotein, additionally protects drug-resistant tumor cells from multiple forms of caspase-dependent apoptosis. Proc Natl Acad Sci USA 95:7024, 1998
24. Walter RJ, Shtil AA, Roninson IB, Holian O: 60-Hz electric fields inhibit protein kinase C activity and multidrug resistance gene (MDR1) up-regulation. Radiat Res 147:369, 1997
25. Rappa G, Lorico A, Liu M-C, Kruh GD, Cory AH, Cory JG, Sartorelli AC: Overexpression of the multidrug resistance genes mdr1, mdr3, and mrp in L1210 leukemia cells resistant to inhibitors of ribonucleotide reductase. Biochem Pharmacol 54:649, 1997
26. Holló Z, Homolya L, Davis CW, Sarkadi B: Calcein accumulation as a fluorimetric functional assay of the multidrug transporter. Biochem Biophys Acta 1191:384, 1994
27. Montaudon D, Pourquier P, Denois F, de Tinguy-Moreaud E, Lagarde P, Robert J: Differential stabilization of topoisomerase-II-DNA cleavable complexes by doxorubicin and etoposide in doxorubicin-resistant rat glioblastoma cells. Eur J Biochem 245:307, 1997
28. Mahvi DM, Burkholder JK, Turner J, Culp J, Malter JS, Sondel PM, Yang NS: Particle-mediated gene transfer of granulocyte-macrophage colony stimulating factor cDNA to tumor cells: Implications for a clinically relevant tumor vaccine. Hum Gene Ther 7:1535, 1996
29. Rakhmilevich AL, Turner J, Ford MJ, McCabe D, Sun WH, Sondel PM, Grota K, Yang N-S: Gene gun-mediated skin transfection with interleukin 12 gene results in regression of established primary and metastatic murine tumors. Proc Natl Acad Sci USA 93:6291, 1996
30. Kataoka T, Shinohara N, Takayama H, Takaku K, Kondo S, Yonehara S, Nagai K: Concanamycin A, a powerful tool for characterization and estimation of contribution of perforin- and Fas-based lytic pathways in cell-mediated cytotoxicity. J Immunol 156:3678, 1996
31. Wyler B, Shao Y, Schneider E, Cianfriglia M, Scheper RJ, Frey BM, Gieseler F, Schmid L, Twentyman PR, Lehnert M: Intermittent exposure to doxorubicin in vitro selects for multifactorial non-P-glycoprotein-associated multidrug resistance in RPMI 8226 human myeloma cells. Br J Haematol 97:65, 1997
32. Raaijmakers HG, Izquierdo MA, Lokhorst HM, de Leeuw C, Belien JA, Bloem AC, Dekker AW, Scheper RJ, Sonneveld P: Lung-resistance-related protein expression is a negative predictive factor for response to conventional low but not to intensified dose alkylating chemotherapy in multiple myeloma. Blood 91:1029, 1998
33. Valkov NI, Sullivan DM: Drug resistance to DNA topoisomerase I and II inhibitors in human leukemia, lymphoma, and multiple myeloma. Semin Hematol 34:48, 1997
34. Wang H, Jiang Z, Wong, YW, Dalton W.S, Futscher BW, Chan VT: Decreased CP-1 (NF-Y) activity results in transcriptional down-regulation of topoisomerase II alpha in a doxorubicin-resistant variant of human multiple myeloma RPMI 8226. Biochem Biophys Res Commun 237:217, 1997
35. Ganapathi R, Grabowski D, Schmidt H, Bell D, Melia M: Characterization in vitro and in vivo of progressively Adriamycin-resistant B16-B16 mouse melanoma cells. Cancer Res 47:3464, 1987
36. Shtil A, Shushanov A, Moynova E, Stavrovskaya A: Frequency of metastasis in Syrian hamster tumor cells selected in vitro for low-levels of 'typical' multidrug resistance. Exp Toxicol Pathol 46:257, 1994
37. +-ATPase, on CTL-mediated cytotoxicity. J Immunol 153:3938, 1994
38. Berke G: The binding and lysis of target cells by cytotoxic lymphocytes: Molecular and cellular aspects. Annu Rev Immunol 12:735, 1994
39. Thornberry NA, Rano TA, Peterson EP, Rasper DM, Timkey T, Garcia-Calvo M, Houtzager VM, Nordstrom PA, Roy S, Vaillancourt JP, Chapman KT, Nicholson DW: A combinatorial approach defines specificities of members of the caspase family and granzyme B. J Biol Chem 272:17907, 1997
40. Atkinson EA, Barry M, Darmon AJ, Shostak I, Turner PC, Moyer RW, Bleakley RC: Cytotoxic T-lymphocyte-assisted suicide. Caspase 3 activation is primarily the result of the direct action of granzyme B. J Biol Chem 273:21261, 1998